Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome

Blood. 2020 Oct 22;136(17):1980-1983. doi: 10.1182/blood.2020005123.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / adverse effects
  • Adenine / analogs & derivatives
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell Transdifferentiation* / genetics
  • Cell Transdifferentiation* / immunology
  • Cellular Reprogramming / genetics
  • Cellular Reprogramming / immunology
  • Cellular Reprogramming / physiology
  • Combined Modality Therapy
  • Epigenesis, Genetic / physiology
  • Epigenome / immunology
  • Gene Rearrangement
  • Genes, Immunoglobulin Heavy Chain / genetics
  • Humans
  • Immunotherapy / adverse effects*
  • Immunotherapy / methods
  • Lymph Nodes / pathology
  • Lymphoma, Mantle-Cell / genetics
  • Lymphoma, Mantle-Cell / immunology
  • Lymphoma, Mantle-Cell / therapy*
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / etiology*
  • Piperidines / administration & dosage
  • Piperidines / adverse effects
  • Receptors, Antigen, T-Cell / therapeutic use
  • Rituximab / administration & dosage
  • Rituximab / adverse effects
  • Sarcoma / etiology*
  • Sarcoma / genetics
  • Sarcoma / immunology
  • Sarcoma / pathology
  • Transplantation, Autologous / adverse effects
  • Tumor Cells, Cultured

Substances

  • CTL019 chimeric antigen receptor
  • Piperidines
  • Receptors, Antigen, T-Cell
  • ibrutinib
  • Rituximab
  • Adenine